Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan-based conditioning with rapamycin-based graft-versus-host disease prophylaxis before mismatched allogeneic hematopoietic stem cell transplantation
2007-005477-54Phase 2Terminated
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan, sirolimus, fludarabine, mycophenolic acid, rituximab in hematopoietic malignancies, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS), sponsored by IRCCS Ospedale San Raffaele. Started Jan 2008; status: terminated.
02
Drugs
treosulfansirolimusfludarabinemycophenolic acidrituximab
03
Conditions
hematopoietic malignanciesacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2007-005477-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005477-54.